Welcome to our dedicated page for Golden Sun Health Technology Group SEC filings (Ticker: GSUN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Golden Sun Health Technology Group Limited (GSUN) SEC filings page on Stock Titan provides access to the company’s reports and disclosures filed with the U.S. Securities and Exchange Commission. As a foreign private issuer with shares listed on the Nasdaq Capital Market, Golden Sun submits Form 6-K current reports and other Exchange Act filings that describe corporate actions, governance decisions, and material developments.
In its Form 6-K filings, Golden Sun has reported on shareholder meetings, including extraordinary general meetings and annual general meetings. These filings detail matters such as the re-election of directors, the appointment and ratification of Assentsure PAC as independent registered public accounting firm, adoption of a financial year ending on September 30, and changes to the company’s name and constitutional documents. They also describe resolutions to increase authorized share capital and to vary the voting rights attached to Class B ordinary shares, providing insight into the company’s dual-class share structure and capital planning.
Other 6-K reports cover listing and compliance topics, such as responses to Nasdaq notifications about minimum bid price deficiencies and related actions like a 1-for-10 share consolidation of ordinary shares. These filings help investors understand how the company addresses continued listing requirements and manages potential delisting risks.
Golden Sun’s filings also include disclosures about executive changes. For example, a Form 6-K describes the resignation of a chief operating officer for personal reasons and the appointment of a new chief operating officer, along with a summary of the executive’s prior roles in cross border e-commerce, cultural and tourism planning services, information technology services, asset management, and trust business. The filing outlines key terms of the employment agreement, including its duration, compensation, renewal conditions, and grounds for termination, as well as standard confidentiality and non-disclosure covenants.
On Stock Titan, these SEC filings are updated as they are made available through EDGAR. AI-powered tools can assist users by summarizing lengthy documents, highlighting key resolutions and structural changes, and making it easier to follow Golden Sun’s corporate governance, capital structure adjustments, and management changes over time.
Golden Sun Technology Group Limited, a Cayman holding company with operations in China, reports a major shift from education into e-commerce marketing services. More than 90% of revenue now comes from data‑driven promotion and advertising support on Chinese short‑video platforms, while tutorial services are maintained only on a limited basis.
For the fiscal year ended September 30, 2025, revenue from continuing operations rose to approximately $35.5 million, up about $29.4 million or 483%, mainly from e‑commerce expansion. Despite this growth, the company recorded a net loss of about $5.2 million, 32% higher than the prior year, and its auditor expressed substantial doubt about its ability to continue as a going concern.
As of September 30, 2025, Golden Sun reported an accumulated deficit of $23.6 million, cash of roughly $0.8 million, current assets of about $12.7 million and current liabilities of about $10.6 million. The company implemented a one‑for‑ten share consolidation and, as of that date, had 8,325,870 Class A and 403,000 Class B ordinary shares outstanding. It also changed its name to reflect its new technology and e‑commerce strategy, while highlighting extensive regulatory, licensing, data‑security, tax and PRC policy risks, including exposure to evolving rules on private education, e‑commerce compliance and U.S. oversight under the HFCA Act.
Golden Sun Technology Group Limited has changed its corporate name from “Golden Sun Health Technology Group Limited” to “Golden Sun Technology Group Limited.” The company expects its Class A ordinary shares to begin trading on the Nasdaq Capital Market under the new name on February 5, 2026, while its CUSIP number will stay the same.
The company explains that the new name reflects its updated business strategy and future development plans, including its shift since November 2023 from a primary focus on tutorial services toward data analytics–driven e-commerce marketing and social media promotion services for small and medium-sized businesses in China.
The filing presents the matters submitted for shareholder approval at Golden Sun Technology Group Limited's upcoming meeting. Shareholders are asked to re-elect seven directors and ratify the re-appointment of AssentSure PAC as the company’s independent registered public accounting firm. Two related special resolutions seek to change the company’s English and dual foreign names to remove the word "Health" and to adopt amended constitutional documents to reflect that name change. Another special resolution would implement a Class B variation subject to Class A and B consent. The company also proposes a sizable increase in authorized share capital from US$50,000 to US$1,000,000 and related amendments to the memorandum, plus an ordinary resolution to allow adjournment of the AGM if further proxy solicitation is needed.
Golden Sun Health Technology Group Limited reported a change in its chief operating officer role. On September 18, 2025, Ms. Xiaoyi Wang resigned as COO for personal reasons, and the company stated her departure did not involve any dispute with management or the board. The board appointed Mr. Duo Ye as the new COO, effective the same day.
Mr. Ye brings more than a decade of senior management experience across financial services, asset management, cultural media, and cross-border e-commerce. On September 24, 2025, the company entered into a three-year employment agreement with him, running from September 18, 2025 to September 17, 2028, with automatic renewal unless either party gives two months’ notice. He will receive a monthly salary of $3,233 plus standard benefits, and the agreement allows termination for cause and includes customary confidentiality and non-disclosure covenants. The company states there are no family relationships or related-party transactions involving Mr. Ye.
Golden Sun Health Technology Group Limited reported that on August 27, 2025 it received formal notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the minimum stockholders’ equity requirement for listing on The Nasdaq Capital Market. The company now meets all applicable criteria for continued listing, although Nasdaq will continue to monitor its status and could initiate a new delisting process if future periodic financial statements show that it no longer satisfies the minimum stockholders’ equity rule.
Golden Sun Health Technology Group Limited reports that its two accredited investors have fully exercised their warrant and converted all principal and interest under a prior convertible note into equity. On August 22, 2025, this transaction resulted in the issuance of 6,747,926 Class A ordinary shares to the investors. The original note had an aggregate principal amount of $5,000,000.
The company states that the carrying value of the note and warrant, about $9.4 million as of March 31, 2025, will be reclassified to total equity as of August 25, 2025. Because this increases shareholders’ equity, the company believes it now meets Nasdaq’s minimum $2.5 million shareholder equity requirement for continued listing and is waiting for a formal compliance determination from Nasdaq staff.
Form 144 notice by an insider of Golden Sun Health Technology Group Limited (GSUN) reporting a proposed sale of Class A ordinary shares. The filing lists a proposed sale of 140,108 Class A ordinary shares through WestBull Securities Limited (Hong Kong) on the Nasdaq with an aggregate market value of $378,291.60 and 1,577,944 shares outstanding reported. The table discloses prior acquisitions of Class A shares: 14,460 shares purchased 04/02/2020, 57,840 shares purchased 10/19/2020, and 4,820 shares purchased 10/19/2020, with payment in USD. The filer attests they possess no undisclosed material adverse information and includes the standard Rule 144 and signature attestations.
Golden Sun Health Technology Group Limited is notifying investors about upcoming shareholder meetings and related proxy materials. The company will hold an extraordinary general meeting for holders of Class A ordinary shares on September 25, 2025, followed by its 2025 annual general meeting of shareholders on the same date.
The company is distributing a combined notice and proxy statement for Class A shareholders and a separate notice and proxy statement for Class B shareholders, both dated August 15, 2025. It is also providing proxy cards for Class A and Class B holders so they can vote on the matters to be presented at these meetings.
Golden Sun Health Technology Group Limited filed an amended Form 6-K to add details about an amendment to its existing financing. The company had previously issued a Senior Secured Convertible Note with an aggregate principal amount of $5,000,000 to two accredited investors under a Securities Purchase Agreement dated October 28, 2024, with closing on December 3, 2024. On August 15, 2025, the company and these investors signed Amendment No. 1 to the note, which removes the Adjusted Floor Price defined in the original note and any related adjustments. The amendment is attached as Exhibit 4.1 and this amended Form 6-K is also incorporated by reference into the company’s effective Form F-1 registration statement and related prospectuses.
Golden Sun Health Technology Group Limited furnished a Form 6-K that is incorporated by reference into its effective Form F-1 registration statement. The filing states that Unaudited Condensed Consolidated Financial Statements as of March 31, 2025 and for the six months ended March 31, 2025 and 2024 are attached as Exhibit 99.1, and that an Operating and Financial Review and Prospects for the same periods is attached as Exhibit 99.2.
The report contains a detailed cautionary statement about forward-looking statements and lists key risk assumptions including financial projections, growth and expansion execution, economic and political conditions, capital requirements, talent retention, competition in the education industry, and other assumptions. The document is signed on the company’s behalf by its Chief Executive Officer.